Search

BOSTON: EMD Serono has issued the following news release: EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced presentations showcasing the long-term [...]

* Phase IV studies demonstrate the consistent safety and high efficacy of MAVENCLAD on NEDA-3, MRI and cognition outcomes over four years * New data on blood and CSF biomarkers [...]

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced presentations showcasing the long-term safety profile, sustained efficacy data, and durable effect of [...]

ROCKLAND: EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of two new post-hoc analyses of tertiary endpoints from the MAGNIFY-MS [...]

* In a post-hoc analysis, new data reveal evidence of cognitive benefit in RMS after the initial course of MAVENCLAD([R]) (cladribine) tablets, with sustained cognitive improvement or stability observed at [...]

Germany: Merck KGaA has issued the following press release: New data showed sustained reduction in neurofilament light chain (NfL) levels over two years of treatment with MAVENCLAD(r) (cladribine tablets) in [...]

Adalvo has made significant progress in the development of Cladribine, a treatment for Multiple Sclerosis. The product has shown promising sales, generating around $1064 million globally in 2022 with a [...]

DARMSTADT: Merck, a leading science and technology company, today announced the presentation of new analyses from the MAVENCLAD(r) (cladribine tablets) MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis [...]

ROCKLAND: EMD SERONO has issued the following news release: EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of [...]

ENPNewswire-October 11, 2023--Merck Presents New MAVENCLAD Data at the 9th Joint ECTRIMS-ACTRIMS congress in Milan (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 10102023 - GERMANY - Merck, a leading science and [...]

Germany, Oct. 10 -- New data showed sustained reduction in neurofilament light chain (NfL) levels over two years of treatment with MAVENCLAD(R) (cladribine tablets) in patients with relapsing multiple sclerosis [...]

* New data showed sustained reduction in neurofilament light chain (NfL) levels over two years of treatment with MAVENCLAD([R]) (cladribine) tablets in patients with relapsing multiple sclerosis (RMS) * Findings [...]

Merck, a leading science and technology company, has reported 1Q 2023 results. In the 1Q 2023, sales of the Healthcare business sector increased by 6.2% to EUR 1905 M. Organic growth was 5.3%. Foreign exchange had a positive effect of 0.8% on sales growth. The key growth drivers were once again new Healthcare products: The immuno-oncology drug Bavencio generated an organic sales increase of 30.6%. Sales of Mavenclad for the treatment of relapsing multiple sclerosis grew organically by 23.0%. Both the Fertility and the Cardiovascular, Metabolism & Endocrinology franchises saw organic sales growth of their portfolio products. EBITDA pre of Healthcare rose by 11.4% to EUR 590 M in the 1Q 2023. Organic growth was 10.5%, supported by positive foreign exchange effects of 0.9%. The EBITDA pre margin of the business sector came in at 30.9%. Original source: Merck KGaA, website: https://www.merckgroup.com/en, Copyright Merck KGaA 2023., company results; anticancer drugs; Bavencio; immunotherapeutics; Mavenclad; multiple sclerosis drugs; [...]

Germany, Feb. 24 -- Data from the ongoing Phase II extension showed treatment benefits of evobrutinib were maintained over four years and remained consistent with the efficacy and safety profile [...]

* Data from the ongoing Phase II extension showed treatment benefits of evobrutinib were maintained over four years and remained consistent with the efficacy and safety profile seen in earlier [...]

Merck, a leading science and technology company, continued its growth trajectory in the 2Q 2022 despite a challenging environment. In the 2Q 2022, the Healthcare business sector reported organic sales growth of 1.4%. The strong previous year quarter was favourably impacted by around EUR 50 M from the temporary contract manufacturing for Eli Lilly and Company, US, (Eli Lilly). Including positive foreign exchange effects of 6.2%, net sales amounted to EUR 1924 M, an increase of 7.6%. The key growth driver was business with new products such as Bavencio and Mavenclad. In the 2Q 2022, the Oncology franchise delivered organic growth of 8.1%, which was fuelled especially by the strong 60.7% increase in sales of the immuno-oncology drug Bavencio. This increase was primarily attributable to the further gain of market shares in connection with first-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma (UC), particularly in Europe and Japan. The oncology drug Erbitux saw an organic sales decline of -9.0% owing to the temporary contract manufacturing agreement with Eli Lilly in the 2Q 2021. Sales of the Neurology & Immunology franchise declined organically by -1.2%. Mavenclad, for the treatment of relapsing multiple sclerosis, generated organic sales growth of 26.6%. The multiple sclerosis drug Rebif saw a decrease of -18.9%. The Fertility franchise recorded a moderate organic sales decline of -2.7% in the 2Q 2022, while the Cardiovascular, Metabolism and Endocrinology franchise grew moderately by 2.7%. In the 2Q 2022, EBITDA pre of the Healthcare business sector increased by 3.9% compared with the 2Q 2021 to EUR 604 M. An organic earnings decline of -9.5% was countered by positive foreign exchange effects of 13.4%. The strong result of the 2Q 2021 was supported by the temporary supply agreement with Eli Lilly. The EBITDA pre margin was 31.4%. Original source: Merck KGaA, website: https://www.merckgroup.com/en, Copyright Merck KGaA 2022., company results; anticancer drugs; Bavencio; beta-interferon; cetuximab; Mavenclad; multiple sclerosis drugs; [...]

DARMSTADT, Germany: Merck has issued the following news release: Merck, a leading science and technology company, today announced 13 abstracts from the Company's multiple sclerosis (MS) portfolio will be presented [...]

ROCKLAND, Mass.: EMD Serono has issued the following news release: EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced 13 abstracts [...]

- Multiple sclerosis is a chronic and unpredictable disease of the central nervous system and is thought to be an immune-mediated disorder, in which the immune system attacks healthy tissue [...]

- Multiple sclerosis is a chronic and unpredictable disease of the central nervous system and is thought to be an immune-mediated disorder, in which the immune system attacks healthy tissue [...]

- Multiple sclerosis is a chronic and unpredictable disease of the central nervous system and is thought to be an immune-mediated disorder, in which the immune system attacks healthy tissue [...]